Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

Patients with locally advanced and metastatic urothelial carcinoma have a low survival rate (median 15.7 months, 13.1–17.8), with only a 23% response rate to monotherapy treatment with anti-PDL1 checkpoint immunotherapy. To identify new therapeutic targets, we profiled the immune regulatory signatur...

Full description

Bibliographic Details
Main Authors: Joseph R. Podojil, Alexander P. Glaser, Dylan Baker, Elise T. Courtois, Damiano Fantini, Yanni Yu, Valerie Eaton, Santhosh Sivajothi, Mingyi Chiang, Arighno Das, Kimberly A. McLaughlin, Paul Robson, Stephen D. Miller, Joshua J. Meeks
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
immunotherapy
bladder cancer
macrophage
t cell
checkpoint inhibitor
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1744897

Internet

http://dx.doi.org/10.1080/2162402X.2020.1744897

Similar Items